Biophytis Sa · EURONEXT:ALBPS
Biophytis Sa — Investor Presentation (February 2021)
29 slides from Biophytis Sa's investor presentation, February 2021
Slide 1: February 2021 I Euronext, EPA: ALBPS
February 2021 I Euronext, EPA: ALBPS
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential
Slide 3: A clinical-stage biotechnology company specialized in age-related diseases
A clinical-stage biotechnology company specialized in age-related diseases COVID-19 & Our goal Retinal diseases Neuromuscular diseases Prevent disabilities (muscular, Drug candidate Sarconeos (BIO101) Pre-clinical drug candidate respiratory and vision) and in clinical development for : Macuneos (BIO
Slide 4: Modern drug discovery process, inspired by traditional medicine
Modern drug discovery process, inspired by traditional medicine Our technology Reverse pharmacology for drug Sarconeos (BIO 101) candidates in Age Related diseases Macuneos (BIO201) Build a proprietary Screen in Selection of collection of cellular models best drug • Small molecules: natural natu
Slide 5: Executive team
Executive team Samuel Agus - CMO Stanislas Veillet - Founder & CEO • MD, PhD, Board-certified Neurologist • PhD in genetics, AgroParisTech • 15+ years pharma/biotech experience • 25+ years in biotech; Pharmacia-Monsanto, including Abbott, Shire and Teva Danone Group Pharmaceuticals Pierre Dilda - CS
Slide 6: Our clinical pipeline
Our clinical pipeline Candidate Indication Program Preclinical Phase 1 Phase 2 Phase 3 Covid-19 COVA Sarconeos Sarcopenia SARA (BIO101) DMD MYODA Dry AMD MACA Macuneos (BIO201) Stargardt • Second generation drug candidates, BIO103 and BIO203, are life-cycle extension candidates in the preclinical Ph
Slide 7: Key milestones
Key milestones ✓ ✓ COVA started in the Belgium, Brazil, France and US COVA completion of patient enrollment (Part 1) in January 2021 COVA interim analysis expected in Q1 2021 COVA completion of patient enrollment (Part 2) expected in Q1 2021 COVA topline results and expected in Q2 2021 ✓ ✓
Slide 8: Sarconeos (BIO101) activates MAS receptor, a key factor for muscle and respiratory functions
Sarconeos (BIO101) activates MAS receptor, a key factor for muscle and respiratory functions • MAS receptor: a key component of the Renin-Angiotensin System (RAS) • Triggers two important downstream signaling-pathways in myocytes: MAS PI3K/AKT/mTOR: Increases protein synthesis, Receptor preserving m
Slide 9: Sarconeos (BIO101) for respiratory failure in COVID-19
Sarconeos (BIO101) for respiratory failure in COVID-19 • SARS-CoV-2 uses ACE2 to penetrate the lungs destabilizing RAS system and causing respiratory failures • Sarconeos (BIO101) activates MAS receptor, a key component of the protective arm of the RAS system 9
Slide 10: We believe Sarconeos (BIO101) improves muscle strength and mobility in animal model
We believe Sarconeos (BIO101) improves muscle strength and mobility in animal model Beneficial effect on mobility Preservation of muscle strength in aged mice fed with high fat diet1 in immobilized mice Administration of 50 mg/kg/day of Administration of 50 mg/kg/day of Sarconeos (BIO101) demonstrat
Slide 11: Early data suggests Sarconeos (BIO101) improves respiratory functions in animal model
Early data suggests Sarconeos (BIO101) improves respiratory functions in animal model Improves the time-dependent Improves lungs mechanical degradation of respiratory properties2 function1 Chronic (8 week) daily administration of C57BL10-mdx mice treated with 50 50 mg/kg/day of Sarconeos (BIO101) mg
Slide 12: Phase 1 study (SARA-PK) results in elderly healthy volunteers with Sarconeos (BIO101)
Phase 1 study (SARA-PK) results in elderly healthy volunteers with Sarconeos (BIO101) Sarconeos (BIO101) showed a dose dependent effect on muscle growth and repair (PIIINP) and a dose dependent negative e effect on muscle wasting (myoglobin) for Sarconeos BIO101 • Single and multiple ascending doses
Slide 13: Sarcopenia: a large unmet medical need with no currently approved drugs
Sarcopenia: a large unmet medical need with no currently approved drugs • Age-related degeneration of skeletal muscle characterized by a loss of muscle mass, strength and functional issues such as the ability to stand and/or walk • A major cause of mobility disability, resulting in a loss of indepen
Slide 14: SARA-INT: Phase 2 clinical trial in sarcopenia
SARA-INT: Phase 2 clinical trial in sarcopenia • Global, double-blind, randomized, placebo-controlled trial: NCT03452488 • Recruitment completed March 2020 for 233 elderly patients with sarcopenia at risk of mobility disability over 22 centers in the US and Belgium Objectives Key Endpoints Subpopula
Slide 15: SARA-INT: topline results expected in Q2 2021
SARA-INT: topline results expected in Q2 2021 “The SARA-INT Phase 2 trial is investigating a treatment for sarcopenia, a disease of aging which is characterized by loss of muscle mass and function. Recruitment Dr. Roger Fielding, PhD, Director of the Nutrition, Exercise Physiology & Sarcopenia Labor
Slide 16: COVA Study: targeting hospitalized patients with respiratory failure, not intubated
COVA Study: targeting hospitalized patients with respiratory failure, not intubated • Patients aged 45 and above, with proven Target population COVID-19, and severe respiratory symptoms: Severe cases: signs Critical cases: of respiratory de- • With evidence of respiratory decompensation compensation
Slide 17: COVA: Sarconeos (BIO101) evaluating prevention of further respiratory deterioration linked to COVID-19
COVA : Sarconeos (BI0101) evaluating prevention of further respiratory deterioration linked to COVID-19 Part Goal Analysis by the Number of participants • This is a Phase 2/3 DSMB/DMC seamless study design 1. Obtain safety and IA1: 1st interim analysis • Multinational, tolerability data on 1 Decide
Slide 18: DMD: No cure and limited treatment options
DMD: No cure and limited treatment options Proportion of ambulatory class in DMD1 • Rare, genetic neuromuscular disease in male children 100% 90% characterized by accelerated degeneration of muscles, 80% 70% responsible for loss of mobility, respiratory failure and 60% cardiomyopathy, leading to pre
Slide 19: MYODA: IND granted by FDA to start Phase 2/3 clinical study
MYODA: IND granted by FDA to start Phase 2/3 clinical study Product 2020 2021 2022 2023 Sarconeos (BIO101) MYODA (Phase 2/3) Design Patients Regulatory Status • Global, multicenter, double-blind, • Non-ambulatory DMD patients: • Orphan drug designation in US placebo-controlled, seamless, • Part 1: 1
Slide 20: Dry AMD is an unmet medical need with no approved drugs
Dry AMD is an unmet medical need with no approved drugs Projection of AMD prevalence in North America (in M, mean • AMD is a common eye disorder among people over 50 that projection)1 affects the central part of the retina, known as the macula 25 • Can impair functions such as reading, driving, and
Slide 21: Macuneos (BIO201) mechanism of action: Non-canonical activation of PPARs
Macuneos (BIO201) mechanism of action: Non- canonical activation of PPARs • We believe Macuneos potentially counteracts the phototoxic effects of A2E by selective non- canonical activation of the transrepressive activity of PPAR⍺ and PPARβ/δ in the retina • Most other PPAR ligands mainly exhibit can
Slide 22: Macuneos (BIO201) protects the retina in rodent models of dry AMD and Stargardt disease
Macuneos (BIO201) protects the retina in rodent models of dry AMD and Stargardt disease Preservation of Reduced A2E visual function in mice accumulation in mice Chronic oral administration of Chronic oral administration of Macuneos for 3 and 6 months Macuneos decreased A2E increases ERG amplitude in
Slide 23: Appendix
Appendix 23
Slide 24: Scientific advisory board
Scientific advisory board Pr. Jean Mariani, Chairman Dr. Roger Fielding • Professor of neuroscience and biology of aging • Professor of Medicine, Tufts University School of and Director of Charles Foix Institute of Medicine Longevity at Sorbonne University • Director and Sr. Scientist Jean Mayer USD
Slide 25: Board of directors
Board of directors Stanislas Veillet - Founder & CEO Pr. Jean Mariani • PhD in genetics, AgroParisTech • Professor of neuroscience and biology of aging • 25+ years in biotech; Pharmacia, Monsanto, Danone and Director of Charles Foix Institute of & Cargill Longevity at Sorbonne University • Emeritus
Slide 26: From a Sorbonne University spin-off to a successful clinical-stage biotechnology company: 90M€ raised to date
From a Sorbonne University spin-off to a successful clinical-stage biotechnology company: 90M€ raised to date • Initiated SARA- • Launch of COVA • IPO on Alternext INT Phase 2 project with • Incorporated on Paris that raised clinical trial Sarconeos Sept 26, 2006 €10.0 M • Received orphan (BIO101) i
Slide 27: Intellectual Property portfolio – Neuromuscular & respiratory diseases
Intellectual Property portfolio – Neuromuscular & respiratory diseases • We hold exclusive commercial rights through licenses of each of our drug candidates. • IP is jointly owned with Sorbonne University & sometimes with other academic research institutions1. • Patent portfolio covers 10 patent fam
Slide 28: Intellectual Property portfolio – Retinal Diseases
Intellectual Property portfolio – Retinal Diseases • We hold exclusive commercial rights through licenses of each of our drug candidates. • IP is jointly owned with Sorbonne University & sometimes with other academic research institutions. • Patent portfolio covers 5 patent families, including a tot
Slide 29: Thank you
CONTACTS: Stanislas Veillet – CEO stanislas.veillet@biophytis.com Evelyne NGUYEN – CFO evelyne.nguyen@biophytis.com Thank you Investor relations: investors@biophytis.com Website: www.biophytis.com 29